Premium
Mycophenolate Mofetil
Author(s) -
Sievers Theodore M.,
Rossi Stephen J.,
Ghobrial Rafik M.,
Arriola Edgar,
Nishimura Pamela,
Kawano Marv,
Holt Curtis D.
Publication year - 1997
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1997.tb03082.x
Subject(s) - mycophenolate , mycophenolic acid , imp dehydrogenase , prodrug , pharmacology , medicine , refractory (planetary science) , chemistry , inosine , enzyme , biochemistry , transplantation , biology , astrobiology
Mycophenolate mofetil is the morpholinoethylester prodrug of mycophenolic acid, an agent that inhibits the proliferation of B and T lymphocytes through noncompetitive, reversible inhibition of inosine monophosphate dehydrogenase, a key enzyme in the de novo synthetic pathway of guanine nucleotides. Currently, mycophenolate mofetil is approved for the prevention of acute renal allograft rejection when given in combination with cyclosporine and steroids. Several studies also demonstrated that the agent is effective in the treatment of refractory rejection in renal, heart, and liver transplant recipients, and may have efficacy in the treatment of chronic rejection as well.